Equities researchers at Wedbush issued their Q1 2026 earnings per share (EPS) estimates for Nuvation Bio in a report issued on Thursday, March 6th. Wedbush analyst D. Nierengarten forecasts that the ...

Investment analysts at Wedbush boosted their FY2025 earnings estimates for shares of Fennec Pharmaceuticals in a research ...

In-theater advertising company National CineMedia Inc. is well-positioned to reap the benefits of cinema’s unique proposition ...

Fintel reports that on March 12, 2025, Wedbush downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Outperform to ...

Dan Ives, Wedbush Securities global head of technology research, joins CNBC's 'Squawk on the Street' to discuss outlooks on ...

Despite the recent sell-off in tech stocks, analysts at Wedbush believe that this downturn is temporary and that AI leaders ...

Tesla stock is gaining ground on the heels of two significant news items today. President Trump made a statement of support for the company and its CEO, Elon Musk, and Wedbush put out analysis ...

Market fears over tariffs and growth have hit tech stocks, but Wedbush sees the dip as a buying opportunity for long-term investors ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Wedbush Securities added Tesla (NASDAQ:TSLA) to its Best Ideas List amid what it calls a gut-check moment for the electric vehicle stock, with bears seen as controlling the narrative. "Autonomous ...

Tesla (TSLA) stock has landed on Wedbush’s “best ideas list” as analyst Daniel Ives reaffirmed his bullish stance on the ...